Summary
According to the recently published report 'Proto Oncogene Tyrosine Protein Kinase Src - Drugs In Development, 2022'; Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) pipeline Target constitutes close to 17 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Proto-oncogene tyrosine-protein kinase Src or proto-oncogene c-Src is a non-receptor tyrosine kinase protein that is encoded by the SRC gene. It participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. It plays a role in the activation of other protein tyrosine kinase (PTK) families. It plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1.
The report 'Proto Oncogene Tyrosine Protein Kinase Src - Drugs In Development, 2022' outlays comprehensive information on the Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 6, 1, 1, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Central Nervous System, Genetic Disorders, Infectious Disease and Musculoskeletal Disorders which include indications Non-Small Cell Lung Cancer, Solid Tumor, Colorectal Cancer, Idiopathic Pulmonary Fibrosis, Central Nervous System (CNS) Tumor, Glioblastoma Multiforme (GBM), Melanoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Large Cell Lymphoma (ALCL), Angiosarcoma, Breast Cancer, Bronchiolitis Obliterans, Cervical Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Coronavirus Disease 2019 (COVID-19) Pneumonia, Endometrial Cancer, Esophageal Cancer, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Friedreich Ataxia, Gallbladder Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer, Hepatocellular Carcinoma, Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Disease), Interstitial Lung Fibrosis, Lewy Body Dementia, Liver Cancer, Lung Cancer, Lymphangioleiomyomatosis, Malignant Pleural Mesothelioma, Medullary Thyroid Cancer, Metastatic Brain Tumor, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Pancreatic Cancer, Papillary Thyroid Cancer, Parkinson's Disease, Pneumoconiosis, Psychosis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Salivary Gland Cancer, Soft Tissue Sarcoma, Thyroid Cancer, Triple-Negative Breast Cancer (TNBC), Unspecified Cancer and Uterine Cancer.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)
- The report reviews Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Overview
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
AstraZeneca Plc
Avalyn Pharma Inc
Boehringer Ingelheim International GmbH
Chengdu Fanxi Biopharma Co Ltd
Fratagene Therapeutics Srl
KeifeRx LLC
Lead Discovery Center GmbH
Nanocopoeia LLC
Prous Institute for Biomedical Research SA
Taiwan Liposome Co Ltd
Turning Point Therapeutics Inc
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Drug Profiles
bosutinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
dasatinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs to Inhibit SRC for Friedreich Ataxia - Drug Profile
Product Description
Mechanism Of Action
FNX-006 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ilorasertib - Drug Profile
Product Description
Mechanism Of Action
History of Events
JRP-890 - Drug Profile
Product Description
Mechanism Of Action
nintedanib - Drug Profile
Product Description
Mechanism Of Action
History of Events
nintedanib - Drug Profile
Product Description
Mechanism Of Action
History of Events
Ofev - Drug Profile
Product Description
Mechanism Of Action
History of Events
repotrectinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
saracatinib difumarate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Si-306 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit IGF1R and SRC for Non-Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit SRC for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
TPX-0022 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TPX-0046 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Vargatef - Drug Profile
Product Description
Mechanism Of Action
History of Events
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Dormant Products
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Discontinued Products
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Feb 17, 2022: Zai Lab announces breakthrough therapy designation granted for Repotrectinib in China
Feb 15, 2022: Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV (nintedanib) for PF-ILD
Jan 20, 2022: Turning Point Therapeutics announces FDA clearance of investigational new drug (IND) application for combination of elzovantinib and aumolertinib in EGFR mutant met-amplified non-small cell lung Cancer
Oct 23, 2021: Turning Point Therapeutics presents early clinical data for Repotrectinib from care study in pediatric and young adult patients at SIOP 2021 Virtual Congress
Oct 13, 2021: Turning Point Therapeutics and EQRx announce clinical collaboration to evaluate elzovantinib in combination with aumolertinib in patients with EGFR mutant met-amplified advanced non-small cell lung cancer
Oct 11, 2021: Turning Point Therapeutics to present early clinical data for repotrectinib from the CARE study in pediatric and young adult patients at SIOP 2021 Virtual Congress
Oct 08, 2021: Turning Point Therapeutics presents TRIDENT-1 study clinical data for repotrectinib in NTRK+ advanced solid tumors in plenary session at 2021 AACR-NCI-EORTC Conference
Oct 04, 2021: Turning Point Therapeutics granted Breakthrough Therapy Designation for Repotrectinib treatment in patients with NTRK-positive, TKI-pretreated advanced solid tumors
Sep 30, 2021: Turning Point Therapeutics announces additional details for three data presentations at the 2021 AACR-NCI-EORTC conference
Sep 08, 2021: Turning Point Therapeutics announces early clinical data for Repotrectinib in NTRK fusion-positive advanced solid tumors selected for late-breaker plenary presentation at 2021 AACR-NCI-EORTC conference
Aug 16, 2021: Turning Point Therapeutics initiates TRIDENT-2 clinical study investigating Repotrectinib-Trametinib combination in KRAS G12D mutated advanced solid tumors
Aug 11, 2021: Turning Point Therapeutics granted sixth regulatory designation for Repotrectinib
Jun 17, 2021: Turning Point Therapeutics granted FDA Orphan Drug Designation for TPX-0022 in gastric cancer
May 28, 2021: Zai Lab announces first patient treated in China in the registrational phase 2 TRIDENT-1 study of repotrectinib
May 14, 2021: Study analysis available during ATS 2021 supports long-term treatment with Ofev in patients with systemic sclerosis-associated interstitial lung disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AbbVie Inc, 2022
Pipeline by AstraZeneca Plc, 2022
Pipeline by Avalyn Pharma Inc, 2022
Pipeline by Boehringer Ingelheim International GmbH, 2022
Pipeline by Chengdu Fanxi Biopharma Co Ltd, 2022
Pipeline by Fratagene Therapeutics Srl, 2022
Pipeline by KeifeRx LLC, 2022
Pipeline by Lead Discovery Center GmbH, 2022
Pipeline by Nanocopoeia LLC, 2022
Pipeline by Prous Institute for Biomedical Research SA, 2022
Pipeline by Taiwan Liposome Co Ltd, 2022
Pipeline by Turning Point Therapeutics Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Discontinued Products, 2022
List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
